Implementing a clinical scientist-led screening clinic for hypertrophic and dilated cardiomyopathies

Jane Draper1, Rachel Bastiaenen1,2,3, Gerald Carr-White1,2

  • 1Guy's and St. Thomas' NHS Foundation Trust, St. Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH, UK.

PubMed

Insights

A new clinic led by clinical scientists successfully screened relatives of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) patients. This initiative identified new cases and saved valuable consultant cardiologist time for complex cases.

Area of Science:

  • Cardiology
  • Genetics
  • Clinical Science

Background:

  • Screening for inherited cardiac conditions places a significant burden on healthcare services.
  • Current screening relies on consultant cardiologists, diverting resources from sicker patients.
  • Clinical scientists possess skills in ECG interpretation and echocardiography, suitable for screening evaluations.

Purpose of the Study:

  • To implement and evaluate a novel clinical scientist-led screening clinic.
  • To assess the feasibility and effectiveness of this model for first-degree relatives of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) patients.

Main Methods:

  • A retrospective review of the first 200 patients attending a clinical scientist-led screening clinic.
  • Patients underwent clinical evaluation, ECG, and echocardiography.
  • The clinic operated independently of cardiology consultants for initial reviews.

Main Results:

  • Out of 200 individuals, 21 (10.5%) were diagnosed with cardiomyopathy or early phenotypic changes.
  • 169 individuals (85%) had normal screenings and were discharged.
  • The clinic saved an estimated 179 consultant clinic appointments.

Conclusions:

  • Clinical scientist-led screening clinics are feasible, effective, and safe for relatives of HCM and DCM patients.
  • This model efficiently identifies individuals with inherited cardiac conditions.
  • The service frees up consultant capacity for patients requiring specialist input.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...